Celladon Corporation Company Profile

06:01 EDT 30th June 2015 | BioPortfolio

Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The company’s products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Celladon’s first product candidate, MYDICAR®, delivers the gene for the SERCA2a enzyme and is currently being tested in Phase 1 and 2 clinical trials. Celladon is also developing traditional small molecule activators of SERCA2a for the treatment of heart failure. To learn more about Celladon, visit Celladon’s website at www.celladon.net.

Location

2223 Avenida de la Playa #206
La Jolla
California
92037
United States of America

Contact

Phone: 858.366.4288
Fax: 858.964.0974
Email: info@celladon.net


News Articles [65 Associated News Articles listed on BioPortfolio]

SoCal's Celladon Slashes 50% of Jobs to Conserve Cash

Celladon Reports First Quarter 2015 Financial Results SAN DIEGO, May 14, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading exper...

HCW starts Celladon at buy

H.C. Wainwright has initiated coverage of Celladon (NASDAQ:CLDN) with a “buy” rating and price target of $31. The stock closed at $17.79 on Monday. Celladon is focused on developing gene therapy t...

Roth starts Celladon at buy

Roth Capital Partners has initiated coverage of Celladon (NASDAQ:CLDN) with a “buy” rating and 12-month price target of $70. The stock closed at $19.64 on Wednesday. Celladon is expected to announ...

Novasep to supply ingredient for Celladon’s Mydicar

French active ingredients company Novasep and US biotech firm Celladon Corp, a clinical-stage cardiovascular…

Celladon tanks as gene therapy Mydicar fails in mid-stage trial

Celladon Corp has revealed that its Phase IIb CUPID2 trial did not meet its primary and secondary endpoints.

Celladon to suspend Mydicar development, make job cuts and seeks merger

Celladon has issued a business update detailing its intention to suspend further development of its experimental…

Celladon says sell, sell, sell

Celladon has officially thrown in the towel on its gene therapy work, telling investors on 26 June that the biotech has stopped work on all assets and is hoping to sell off everything, or liquidate.

Celladon Reports Negative Results For CUPID2 Trial Of MYDICAR In Advanced Heart Failure

- Investigational gene therapy fails to meet primary and secondary endpoints -- Investor conference call and webcast Monday at 8:30 a.m. ET (5:30 a.m. PT) - SAN DIEGO, April 26, 2015 (GLOBE NEWSWIRE)...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Celladon Corp.

Celladon Corp., based in La Jolla, Calif., was launched in October 2004 as a privately held biotechnology company with the goal of becoming the leader in developing molecular therapies for the treatme...

Celladon Corporation

Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in develop...

More Information about "Celladon Corporation" on BioPortfolio

We have published hundreds of Celladon Corporation news stories on BioPortfolio along with dozens of Celladon Corporation Clinical Trials and PubMed Articles about Celladon Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celladon Corporation Companies in our database. You can also find out about relevant Celladon Corporation Drugs and Medications on this site too.


Advertisement
 

Relevant Topics

Biotechnology
Latest News Clinical Trials Research Drugs Reports Corporate
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Enzymes
Latest News Clinical Trials Research Drugs Reports Corporate
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record